The Pharmaceutical Journal
Vol 280 No 7490 p206
23 February 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Heparin adverse events in US

Serious adverse reactions experienced by patients using a Baxter Healthcare heparin product in the US have resulted in the company temporarily halting the manufacture of its multiple-dose vials of heparin sodium.

About 350 adverse events associated with the product have been reported to the US Food and Drug Administration since January, compared with fewer than 100 reports for the whole of 2007. Most events have involved patients receiving a high bolus dose.

A spokeswoman for Baxter UK said that the product involved does not have a UK licence and is not sold in the UK.